Dermatology news & research- Page 6 of 12 | Hospital Healthcare Europe

This website is intended for healthcare professionals only.

Dermatology

Sunbed use and melanoma – is there really a link?

Sunbed use and melanoma – is there really a link?

Where next for dupilumab?

Where next for dupilumab?

Dupilumab approved by EC for adolescents with moderate-to-severe atopic dermatitis

Dupilumab approved by EC for adolescents with moderate-to-severe atopic dermatitis

Multiple genes affect risk of asthma, hay fever and eczema

Multiple genes affect risk of asthma, hay fever and eczema

Common skin bacterium puts children with severe eczema at higher risk of food allergy

Common skin bacterium puts children with severe eczema at higher risk of food allergy

Urticaria: not always an allergic reaction

Urticaria: not always an allergic reaction

EU reapproves Cimzia to treat plaque psoriasis

EU reapproves Cimzia to treat plaque psoriasis

Initiative launched to improve people’s understanding of eczema

Initiative launched to improve people’s understanding of eczema

NICE Final Appraisal Determination for guselkumab to treat moderate to severe plaque psoriasis

NICE Final Appraisal Determination for guselkumab to treat moderate to severe plaque psoriasis

NICE issues draft guidance not recommending dupilumab

NICE issues draft guidance not recommending dupilumab

Omalizumab recommended in global chronic urticaria guideline

Omalizumab recommended in global chronic urticaria guideline

New data demonstrates long-term skin clearance in patients treated with guselkumab

New data demonstrates long-term skin clearance in patients treated with guselkumab

NICE Final Appraisal Determination recommends use of brodalumab as cost-effective

NICE Final Appraisal Determination recommends use of brodalumab as cost-effective

New two-year data for guselkumab following positive CHMP opinion

New two-year data for guselkumab following positive CHMP opinion

Marketing authorisation for dupilumab in moderate to severe atopic dermatitis recommended

Marketing authorisation for dupilumab in moderate to severe atopic dermatitis recommended

Brodalumab receives license from the European Commission

Brodalumab receives license from the European Commission

New report reveals little progress on 2014 WHO psoriasis recommendations

New report reveals little progress on 2014 WHO psoriasis recommendations

UK patients granted early access to Sanofi’s dupilumab by MHRA

UK patients granted early access to Sanofi’s dupilumab by MHRA

x